327 related articles for article (PubMed ID: 15481438)
1. Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.
Kinoshita T
Int J Hematol; 2004 Aug; 80(2):108-19. PubMed ID: 15481438
[TBL] [Abstract][Full Text] [Related]
2. Role of epigenetic changes in hematological malignancies.
Lehmann U; Brakensiek K; Kreipe H
Ann Hematol; 2004 Mar; 83(3):137-52. PubMed ID: 15064862
[TBL] [Abstract][Full Text] [Related]
3. Beyond genetics--the emerging role of epigenetic changes in hematopoietic malignancies.
Galm O; Esteller M
Int J Hematol; 2004 Aug; 80(2):120-7. PubMed ID: 15481439
[TBL] [Abstract][Full Text] [Related]
4. Alterations of DNA methylation in hematologic malignancies.
Rush LJ; Plass C
Cancer Lett; 2002 Nov; 185(1):1-12. PubMed ID: 12142073
[TBL] [Abstract][Full Text] [Related]
5. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg.
Esteller M
Clin Immunol; 2003 Oct; 109(1):80-8. PubMed ID: 14585279
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies.
Fraga MF; Berdasco M; Ballestar E; Ropero S; Lopez-Nieva P; Lopez-Serra L; Martín-Subero JI; Calasanz MJ; Lopez de Silanes I; Setien F; Casado S; Fernandez AF; Siebert R; Stifani S; Esteller M
Cancer Res; 2008 Jun; 68(11):4116-22. PubMed ID: 18519670
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of gene promoters in hematological neoplasia.
Chim CS; Liang R; Kwong YL
Hematol Oncol; 2002 Dec; 20(4):167-76. PubMed ID: 12469326
[TBL] [Abstract][Full Text] [Related]
8. CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies.
Sun C; Duan P; Luan C
Curr Drug Targets; 2017; 18(10):1142-1151. PubMed ID: 28031014
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
11. Gene silencing by DNA methylation in haematological malignancies.
Boultwood J; Wainscoat JS
Br J Haematol; 2007 Jul; 138(1):3-11. PubMed ID: 17489980
[TBL] [Abstract][Full Text] [Related]
12. The fundamental role of epigenetics in hematopoietic malignancies.
Galm O; Herman JG; Baylin SB
Blood Rev; 2006 Jan; 20(1):1-13. PubMed ID: 16426940
[TBL] [Abstract][Full Text] [Related]
13. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
Drexler HG
Leukemia; 1998 Jun; 12(6):845-59. PubMed ID: 9639410
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modulation in hematologic malignancies: challenges and progress.
Mitsiades CS; Anderson KC
J Natl Compr Canc Netw; 2009 Nov; 7 Suppl 8():S1-12; quiz S14-6. PubMed ID: 19930971
[TBL] [Abstract][Full Text] [Related]
16. CDKN2 (MTS1/p16INK4A) gene alterations in hematological malignancies.
Uchida T; Kinoshita T; Saito H; Hotta T
Leuk Lymphoma; 1997 Feb; 24(5-6):449-61. PubMed ID: 9086436
[TBL] [Abstract][Full Text] [Related]
17. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma.
Qiu GH; Tan LK; Loh KS; Lim CY; Srivastava G; Tsai ST; Tsao SW; Tao Q
Oncogene; 2004 Jun; 23(27):4793-806. PubMed ID: 15122337
[TBL] [Abstract][Full Text] [Related]
18. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
19. SRARP and HSPB7 are epigenetically regulated gene pairs that function as tumor suppressors and predict clinical outcome in malignancies.
Naderi A
Mol Oncol; 2018 May; 12(5):724-755. PubMed ID: 29577611
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis.
Chen W; Cooper TK; Zahnow CA; Overholtzer M; Zhao Z; Ladanyi M; Karp JE; Gokgoz N; Wunder JS; Andrulis IL; Levine AJ; Mankowski JL; Baylin SB
Cancer Cell; 2004 Oct; 6(4):387-98. PubMed ID: 15488761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
